|
US2021059930A1
|
|
Use of alpha-2-adrenergic receptor agonists for improving vision
|
|
WO2021021646A1
|
|
Compositions and methods for treatment of presbyopia
|
|
US2021015908A1
|
|
Methods for treating and for inhibiting progression of seizures
|
|
WO2020231869A1
|
|
Implant identification by radiographic means
|
|
WO2020219707A1
|
|
Compositions and methods for treatment of ocular conditions
|
|
WO2020163495A1
|
|
Combination therapy using clostridial toxin derivative and at least one chemical depolarizing agent
|
|
US2020038133A1
|
|
Multiple needle injector
|
|
WO2020056369A1
|
|
Tissue expansion device
|
|
CA3112394A1
|
|
Clostridial toxin - hyaluronic acid compositions
|
|
CA3112227A1
|
|
Methods for treatment of masseter muscle hypertrophy
|
|
AU2019325486A1
|
|
The use of alpha-2-adrenergic receptor agonists for improving vision
|
|
US2020054869A1
|
|
Microneedle array with active ingredient
|
|
EP3801458A1
|
|
Screening assay to assess topical delivery of biological therapeutic agents
|
|
BR112020023071A2
|
|
method of distribution of biological agents from a topical formulation
|
|
CN112272578A
|
|
Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity
|
|
EP3681500A2
|
|
Use of pilocarpine hydrochloride for the treatment of ocular conditions
|
|
KR20200101953A
|
|
Botulinum toxin cell binding domain polypeptide and methods of use for treatment of fibrosis associated disorders
|
|
US2019192341A1
|
|
Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
|
|
TW201922758A
|
|
Enamines and diastereo-selective reduction of enamines
|
|
AU2018318075A1
|
|
3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
|
